Literature DB >> 24000257

Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition.

Joanne A Groeneveldt, Steven J M Gans, Harm J Bogaard, Anton Vonk-Noordegraaf.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24000257     DOI： 10.1183/09031936.00035913

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  5 in total

Review 1.  Dasatinib-induced pulmonary arterial hypertension.

Authors:  Nurgül Özgür Yurttaş; Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2018-03-06       Impact factor: 4.335

2.  A case of multiple myeloma with metachronous chronic myeloid leukemia treated successfully with bortezomib, dexamethasone, and dasatinib.

Authors:  Samer Alsidawi; Abhimanyu Ghose; Julianne Qualtieri; Neetu Radhakrishnan
Journal:  Case Rep Oncol Med       Date:  2014-12-02

Review 3.  Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia.

Authors:  Oren Pasvolsky; Avi Leader; Zaza Iakobishvili; Yishay Wasserstrum; Ran Kornowski; Pia Raanani
Journal:  Cardiooncology       Date:  2015-12-04

Review 4.  A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities.

Authors:  Zahra Nekoukar; Minoo Moghimi; Ebrahim Salehifar
Journal:  Blood Res       Date:  2021-12-31

5.  Melatonin Attenuates Dasatinib-Aggravated Hypoxic Pulmonary Hypertension via Inhibiting Pulmonary Vascular Remodeling.

Authors:  Rui Wang; Jinjin Pan; Jinzhen Han; Miaomiao Gong; Liang Liu; Yunlong Zhang; Ying Liu; Dingyou Wang; Qing Tang; Na Wu; Lin Wang; Jinsong Yan; Hua Li; Yuhui Yuan
Journal:  Front Cardiovasc Med       Date:  2022-03-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.